Financière Moncey Société anonyme (EPA:FMONC)

Ligand Pharmaceuticals Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cost of Revenue	0.59	0.58	0.39	0.42	0.38
Gross Profit	-0.59	-0.58	-0.39	-0.42	-0.38
Operating Income	-0.59	-0.58	-0.39	-0.42	-0.38
Interest & Investment Income	1.88	1.6	1.36	1.16	0.49
Earnings From Equity Investments	8.55	12.75	8.79	7.37	18.21
Other Non Operating Income (Expenses)	-0.34	-	-	-0	-
EBT Excluding Unusual Items	9.51	13.78	9.76	8.11	18.33
Pretax Income	9.51	13.78	9.76	8.11	18.33
Income Tax Expense	0.28	0.29	0.27	0.22	0.07
Earnings From Continuing Operations	9.23	13.48	9.49	7.89	18.26
Minority Interest in Earnings	-	-0.02	0.01	0.01	0.01
Net Income	9.23	13.46	9.5	7.9	18.27
Net Income to Common	9.23	13.46	9.5	7.9	18.27
Net Income Growth	-31.40%	41.70%	20.30%	-56.78%	242.23%
Shares Outstanding (Basic)	18	18	18	18	18
Shares Outstanding (Diluted)	18	18	18	18	18
Shares Change (YoY)	0.33%	-	-	-	-
EPS (Basic)	0.50	0.74	0.52	0.43	1.00
EPS (Diluted)	0.50	0.74	0.52	0.43	1.00
EPS Growth	-32.06%	41.70%	20.31%	-56.78%	242.23%
Dividend Per Share	0.280	0.280	0.280	0.280	0.220
Dividend Growth	-	-	-	27.27%	-
EBIT	-0.59	-0.58	-0.39	-0.42	-0.38
Effective Tax Rate	2.90%	2.13%	2.72%	2.76%	0.36%
Advertising Expenses	0.02	0.02	0.01	-	-

Updated Sep 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.